EWTX
Edgewise
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Buy"
MACD Golden Cross
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About EWTX
Edgewise Therapeutics, Inc.
A clinical-stage biopharmaceutical company which develops small molecule therapies for rare muscle diseases
1715 38th St., Boulder, CO 80301
--
Edgewise Therapeutics, Inc., a Delaware corporation incorporated in May 2017, is headquartered in Boulder, Colorado. The company is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing new therapies for serious, rare muscle diseases with unmet medical needs. The Company's lead product candidate, EDG-5506, is an oral small molecule drug designed to address the underlying causes of malnutrition, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). A pipeline of precision drug candidates for major muscle proteins and regulators to address a broad range of genetically defined muscle diseases.
Company Financials
EPS
EWTX has released its 2024 Q4 earnings. EPS was reported at -0.42, versus the expected -0.42, meeting expectations. The chart below visualizes how EWTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available